Malignant Melanoma | Current Treatment: Physician Insights | US | 2017
The malignant melanoma therapy market is emerging from a very dynamic period (notably 2011-2015) characterized by a plethora of new drug approvals and label expansions. The approvals of both immune checkpoint inhibitors (ICIs) and BRAF/MEK-targeted therapies have changed the treatment landscape dramatically. Combination therapies are playing an increasingly greater role in the unresectable recurrent or metastatic setting, including regimens such as Novartis’s Tafinlar plus Mekinist (2014), Roche/Genentech’s Zelboraf plus Cotellic (2015), and Bristol-Myers Squibb’s Opdivo plus Yervoy (2015). Consequently, optimizing sequencing decisions is a key focus for prescribing oncologists, irrespective of patients’ BRAF mutation status.
Related Market Assessment Reports
Report
Autoimmune Encephalitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Autoimmune Encephalitis (US)
Autoimmune encephalitis is a heterogeneous group of immune-mediated inflammatory brain disorders characterized by subacute cognitive decline, psychiatric symptoms, seizures, movement disorders,…
Report
Immune Thrombocytopenic Purpura – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by low platelet counts and an increased risk of bleeding. Current treatment includes immunomodulators, corticosteroids,…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US)
Chronic inducible urticaria (CIndU) comprises multiple chronic urticaria subtypes triggered by specific external stimuli. Compared with chronic spontaneous urticaria (CSU), CIndU appears to…
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Obstructive Pulmonary Disease (US)
The U.S. treatment landscape for COPD is evolving rapidly as long-acting inhalers and newer therapies reshape prescribing behaviors. Real-world claims data show increasing complexity in treatment…
Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
